New antileishmanial and antitrypanosomal drugs
Beschreibung
The aim is to develop a natural product derived LEAD compound with unrivalled potency against a parasitic disease into a clinical drug candidate, through preclinical development. This includes the establishment of a detailed structure-activity relationship (SAR), medicinal chemistry and organic synthesis, ADME-Tox optimization, formulation, and in vivo studies.
Eckdaten
Projektleitung
Projektteam
Dr. Michael Brand, Flavio Gall, Dr. Silvia Gazzola, Luka Raguz, Dr. Stefano Agnello
Projektpartner
BACOBA AG
Projektstatus
abgeschlossen, 09/2016 - 01/2019
Institut/Zentrum
Institut für Chemie und Biotechnologie (ICBT)
Drittmittelgeber
KTI-Projekt / Projekt Nr. 19208.1 PFLS-LS
Projektvolumen
2'043'672 CHF